ICHR vs LRCX: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

LRCX is the larger of the two ($229.44B market cap): the incumbent the market prices for continued execution (14.97x forward earnings, beta 2.01). ICHR is the smaller challenger ($1.05B), cheaper on forward earnings (8.06x): more room to run, but more to prove. On the numbers, ICHR leads on both counts: faster expected revenue growth (32% vs 21%) and a lower forward P/E (8.06x vs 14.97x). The case for LRCX rests on its own driver (AI-driven chip-capex supercycle): if you believe in that, LRCX fits; if you believe in what the numbers show today, ICHR does.

ICHR vs LRCX: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricICHRLRCXWhat it tells you
Market cap$1.05B$229.44BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E8.0614.97Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E399.3627.37Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.902.01Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range14% of range16% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.1816.50How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: ICHR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ICHR and LRCX affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ICHR and LRCX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ICHR and LRCX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Ichor Holdings (ICHR) do?

Ichor Holdings designs, engineers, and manufactures critical fluid delivery subsystems and components used in the tools that make semiconductors. Its core products are gas delivery subsystems (which deliver, monitor, and control the specialty gases used in etch and deposition) and chemical delivery subsystems (which blend and dispense the reactive liquids used in electroplating and cleaning). Ichor is a turnkey outsourcing partner to major original equipment manufacturers, letting them hand off non-critical elements of tool design, production, and support. The company is headquartered in Fremont, California, and was incorporated in 1999.

Full ICHR guide

What does Lam Research (LRCX) do?

Lam Research is one of the largest semiconductor equipment makers in the world, specializing in wafer-fabrication tools used to build integrated circuits. It is a leader in two critical process steps: etch (precisely removing material to carve nanoscale features) and deposition (laying down ultra-thin films of material), along with related cleaning and surface-preparation systems. These steps are repeated hundreds of times to build modern 3D chip structures, and Lam's tools are essential to manufacturing advanced logic and especially memory chips (DRAM and NAND flash). Lam sells its systems to the world's leading chipmakers and foundries, then earns a large, recurring stream of revenue from spare parts, upgrades, and services for its big installed base of tools, which smooths the cyclical equipment-sales business. Demand is driven by capital spending from semiconductor manufacturers, which rises and falls with chip-industry cycles but trends structurally higher as AI, data centers, and advanced devices require more and more sophisticated chips. Headquartered in Fremont, California, Lam is a key enabler of leading-edge and memory chip production.

Full LRCX guide

ICHR vs LRCX: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ICHR drivers: Semiconductor capital equipment recovery; Margin expansion through proprietary content.
  • LRCX drivers: AI-driven chip-capex supercycle; Leadership in etch and deposition.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Customer concentration is severe: Lam Research and Applied Materials together account for the large majority of revenue (roughly 87 percent by one industry estimate), so a pullback in orders from either would hit results hard. For LRCX, semiconductor equipment is highly cyclical, and Lam's new-tool sales swing sharply with chipmaker capital-spending cycles, especially in memory, which is among the most volatile end markets.

ICHR or LRCX: which should you pick?

If the story you believe is ICHR's (Semiconductor capital equipment recovery), ICHR is the more direct way to own it; if it is LRCX's (AI-driven chip-capex supercycle), LRCX is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ICHR and LRCX guides.

ICHR vs LRCX: the full fundamentals

ICHR. As of November 20, 2026 Ichor carries a market cap near $1.05 billion on about $1.1 billion of trailing revenue, roughly 0.95 times sales, down from about 1.65 times in mid-October and about 3.5 times in May. Trailing GAAP profit is barely positive, so the valuation leans on analysts' forecasts of about $1.84 of EPS in 2026 and $3.47 in 2027, which put the forward multiple near 8x. Cash of about $213.5 million still exceeds debt of roughly $119-152 million, and the eight analysts Yahoo Finance tracks have a mean target near $68.

LRCX. At about $184 on November 20, 2026, Lam trades near 27 times trailing earnings and about 15 times analysts' fiscal 2028 EPS estimate of ~$12.27, a sharp compression from roughly 47x trailing in October even though earnings kept rising. The 30 analysts covering it have a mean target of about $362, nearly double the price, which shows how far the market's read on AI-driven memory and logic capex has moved away from the published estimates (fiscal 2027 revenue near $35.4 billion). The next report, estimated for late January 2027, carries consensus EPS of about $2.35 on ~$8.64 billion of revenue.

Headline figures (approximate, November 2026): ICHR shows revenue (ttm) ~$1.1B, q3 2026 revenue ~$329M (+~37% y/y), q3 2026 non-gaap gross margin ~16%, q3 2026 non-gaap eps ~$0.63 vs ~$0.45 expected; LRCX shows revenue (ttm) ~$26.1 billion (September 2026 quarter ~$8.22B, +54% y/y), margins Gross ~51%, operating ~37%, net ~32% (Q1 FY2027 non-GAAP gross 52.4%), net income (ttm) ~$8.45 billion (EPS ~$6.71), p/e (trailing / forward) ~27x / ~15x.

The bottom line: ICHR vs LRCX

ICHR and LRCX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ICHR and LRCX exposure against your real portfolio. It is not an investment adviser.

Wondering how ICHR or LRCX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Ichor Holdings

Ask Walnut's AI anything about ICHR and see how it fits what you own.

FAQ

What is the difference between ICHR and LRCX?

+

Ichor Holdings designs, engineers, and manufactures critical fluid delivery subsystems and components used in the tools that make semiconductors. Lam Research is one of the largest semiconductor equipment makers in the world, specializing in wafer-fabrication tools used to build integrated circuits. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ICHR or LRCX the better stock?

+

Neither is universally better. LRCX is the larger incumbent; ICHR is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ICHR or LRCX?

+

On forward P/E (as of November 2026), ICHR trades at 8.06x and LRCX at 14.97x, so ICHR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ICHR and LRCX?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ICHR vs LRCX?

+

ICHR: Customer concentration is severe: Lam Research and Applied Materials together account for the large majority of revenue (roughly 87 percent by one industry estimate), so a pullback in orders from either would hit results hard. The business is deeply cyclical and tied to volatile fab equipment spending, and gross margins in the low-to-mid teens leave little cushion when volumes fall. Ichor posted a GAAP net loss in 2025 and is only barely profitable on a trailing twelve-month basis (about $3.5 million), and trailing operating cash flow is negative (about -$38 million) as inventory builds for the ramp. Supplier bottlenecks are a fresh risk: delayed shipments cost Ichor its revenue estimate in Q2 and it fell just short of consensus revenue again in Q3, and the stock has fallen about 76% from its 52-week high, which shows how heavily the market is weighing revenue execution. The roughly $195 million at-the-market offering diluted holders, and insiders including the COO sold shares in August and September. Additional risks include input cost pressure, geographic exposure to Asian semiconductor supply chains, potential export controls or trade restrictions, and competition from larger, better-capitalized subsystem suppliers. LRCX: Semiconductor equipment is highly cyclical, and Lam's new-tool sales swing sharply with chipmaker capital-spending cycles, especially in memory, which is among the most volatile end markets. US export restrictions on advanced chipmaking equipment to China are a significant headwind, since China has been a large customer; tighter rules can cut a meaningful slice of revenue. Customer concentration among a handful of large chipmakers, intense competition from Applied Materials and Tokyo Electron, and sensitivity to memory pricing and macro demand all add risk. A downturn in chip capex or escalating trade restrictions would pressure results and the stock. China rose to 35% of revenue in the September 2026 quarter, so any tightening lands on a larger base, and management already expects that share to fall significantly in the December quarter. Valuation has been the other risk: at about 47 times trailing earnings in October the shares priced in a strong fiscal 2027, and the ~42% drop over the three months to November 20, 2026, during a quarter of record revenue, shows how quickly sentiment on AI capex can turn.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ICHR or LRCX; figures are approximate and dated (as of November 2026). Verify current data before investing.